Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.

Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.

Quanterix (NASDAQ: QTRX) is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.

Recruiting a dynamic team of sales professionals to launch an exciting new therapy for the treatment of Schizophrenia.

Caliper Life Sciences (NASDAQ: CALP) is a global research tools company engaged in the sale of new and enabling products, services, and systems to academic, government and and biotech/pharmaceutical researchers worldwide.

RBI, a part of Reed Elsevier (now RELX) a global provider of information-based analytics and decision tools for professional and business customers, enabling them to make better decisions, get better results and be more productive